Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

A teenage patient has become the first in the UK, a hospital said, to receive what medics call a ground-breaking new drug for ...

The second meal effect refers to the phenomenon in which the Glycemic Index GI of a preceding meal can have a lasting impact ...

The study met its primary endpoint with no procedure or device related serious adverse events reportedRUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GCTK) (“Glucotrack” or the “Company” ...

Diabetes can damage your blood vessels over time because high blood sugar weakens their walls.

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

The prospective single arm study was a short-term in-hospital study over a period of four days ... The Company is currently developing a long-term implantable continuous blood glucose monitoring ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

The global remote patient monitoring market, valued at US$24.39 billion in 2023, is forecasted to grow at a robust CAGR of 12 ...

Dr. Medha N. Munshi, geriatrician and endocrinologist at BIDMC leads research on improving care for older adults with diabetes using digital technologies.

Glytec increased its customer base and overall healthcare impact significantly, driven by a combination of over 20 new and expanded client accounts. Across these new and ...